<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the neuronal damage or loss and <z:hpo ids='HP_0002171'>gliosis</z:hpo> at the cellular level in spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3/<z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e>(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>), and evaluate the potential use of neuron-specific enolase (NSE) and protein S 100 B(S100B) serum concentrations as biochemical markers </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Serum concentrations of NSE and S100B were measured in 102 SCA3/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients and 100 healthy subjects matched by sex and age </plain></SENT>
<SENT sid="2" pm="."><plain>The correlations between both markers and age, <z:hpo ids='HP_0011007'>age of onset</z:hpo>, disease duration, CAG repeat size, scores of international cooperative <z:hpo ids='HP_0001251'>ataxia</z:hpo> rating scale(ICARS), and scale for the assessment and rating of <z:hpo ids='HP_0001251'>ataxia</z:hpo>(SARA) were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Compared with the healthy controls, patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> had higher NSE serum concentrations [(6.95 ± 2.83)ng/mL vs (4.83 ± 1.70) ng/mL, P&lt;0.05] and higher S100B serum concentrations [(0.07 ± 0.06) ng/mL vs (0.05 ± 0.02) ng/mL, P&lt;0.05] </plain></SENT>
<SENT sid="4" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients group, NSE levels presented a positive correlation with age, disease duration, ICARS scores and SARA scores, whereas S100B levels did not correlate with age, <z:hpo ids='HP_0011007'>age of onset</z:hpo>, disease duration, ICARS scores and SARA scores </plain></SENT>
<SENT sid="5" pm="."><plain>CAG repeat size did not correlate with the NSE levels and S100B levels in different age groups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Serum NSE might be a useful marker to monitor disease progression and represent the degree of severity of a certain disease </plain></SENT>
<SENT sid="7" pm="."><plain>Elevated S100B serum concentrations in patients compared to healthy controls may suggest an application of this protein as a peripheral marker of brain impairment in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
</text></document>